- Guides patient management with the most up-to-date scientific and clinical information
- Stimulates investigative efforts
- Written by international experts in their fields
This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management.
This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies.
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
Table of Contents- Background: State-of-the-Art and Ongoing Developments
- Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy
- Pathologic Features of Response to Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer: More than Meets the Eye
- Biomarkers Predicting Outcomes Before and After Neoadjuvant Immune Checkpoint Inhibition Therapy for Muscle-Invasive Bladder Cancer
- The Role of Circulating Tumor DNA Analyses
- The Value of Tumor Sample Analyses Before and After Checkpoint Inhibition: Contextualizing the Treatment-Induced Changes in Gene Expression
- Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints
- State-of-the-Art and Future Role of Molecular Biomarkers for Patient Selection
- The Role of Immunotherapy as Bladder-Sparing Solution for Muscle-Invasive and Non-muscle-Invasive Bladder Cancer: Current Status and Future Perspectives
- An Introduction on Immunotherapy in Prostate Cancer
- Preoperative Immunotherapy for Prostate Cancer: From Bench to Bedside
- Clinical Case Debate: Immunotherapy Versus Alternative Therapies in the Neoadjuvant and Adjuvant Setting of Localized, High-Risk Prostate Cancer
- Biomarkers of Immunotherapy Response and the Future Role of Targeted Therapies in Non-metastatic Prostate Cancer
- Cytoreductive Nephrectomy in the Era of Targeted Therapy and Immunotherapy
- Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
- The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC
- Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages
- Safety of Immune Checkpoint Inhibitors in the Peri-operative Setting
- The Gut and Urinary Microbiota: A Rising Biomarker in Genitourinary Malignancies
- The Future of Artificial Intelligence Applied to Immunotherapy Trials
- The Role of Imaging in Tumor Staging and Response Assessment: Envisaging an Application for the Next-Generation Trials
- The Future of Artificial Intelligence Applied to Perioperative Immunotherapy Trials: Prostate Cancer
- The Future of Artificial Intelligence Applied to Perioperative Immunotherapy Trials: Renal Cell Carcinoma
- Clinical Trial Corner
